Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IFPMA

- PMLiVE

NHS to offer two new treatments for drug-resistant superbugs as part of a new subscription-style payment plan

Manufacturers will receive a fixed yearly fee of £10m, instead of receiving individual payments per dose

- PMLiVE

Longitude Prize in final stage of deciding recipients of £8m prize

The prize will be awarded to a team of innovators who develop a point-of-care diagnostic test that will help combat antimicrobial-resistant infections

- PMLiVE

The IMC unites health industry professionals to combat antibiotic resistant infections

The coalition has formed a new call to action in addressing the way infections are managed across healthcare systems

- PMLiVE

The AMR Action Fund is combating antimicrobial resistance, but much more action is needed

By Henry Skinner, Chief Executive Officer of the AMR Action Fund

- PMLiVE

Henry Skinner has been appointed as the first CEO of the AMR Action Fund

The AMR Action Fund is aiming to strengthen and accelerate antibiotic development

- PMLiVE

AMR Action Fund raises $140m from new investors to tackle antimicrobial resistance

New investment adds to initial $1bn raised at the Fund's launch last year

- PMLiVE

Sandoz to acquire GSK’s cephalosporin antibiotic brands for up to $500m

Sandoz, the generics division of Novartis, will pay $350m upfront for three established brands

Can Cinderella save us?

New Oxford research institute established to tackle antimicrobial resistance

Institute has received £100m in funding from Ineos

- PMLiVE

UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

The antibiotic treats infections caused by aerobic Gram-negative bacteria

- PMLiVE

Rethinking our approach to infectious disease preparedness

The importance of long-term strategic investment to prepare for the next threat that emerges

- PMLiVE

MSD launches antibiotic combo Recarbrio in UK

Therapeutic indicated to treat infections caused by Gram-negative bacteria

- PMLiVE

Shionogi’s Gram-negative antibiotic launches in the UK

Novel antibiotic is indicated for use against Gram-negative bacterial infections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links